Revolution Medicines, Inc.RVMD财报
Nasdaq · 医疗保健 · 生物制品（不含诊断物质）
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| The Vanguard Group | 8.93% | 14.6M | — | 2024-02-13 |
| BlackRock, Inc. | 7.90% | 13.0M | — | 2024-01-26 |
| Wellington Management Group LLP | 6.83% | 11.4M | ▼ -2.26pp | 2024-11-08 |
| BB Biotech AG | 3.10% | 5.0M | — | 2024-02-13 |
| Biotechnology Value Fund, L.P. | 1.90% | 3.1M | ▼ -2.50pp | 2024-02-14 |
| Farallon Capital Partners, L.P. | 0.20% | 329.6K | ▼ -0.10pp | 2024-02-12 |
| EcoR1 Capital, LLC | 0.10% | 132.6K | ▼ -6.70pp | 2024-02-14 |
| The Column Group III, LP | 0.00% | 76.2K | — | 2024-02-09 |
内部人交易
Net 90d: −$28.37M · buys $0 / sells $28.37M时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-15 | GOLDSMITH MARK A | See Remarks | Option exercise | 23.2K | $4.09 | $95.1K |
| 2026-04-15 | GOLDSMITH MARK A | See Remarks | Option exercise | 96.8K | $4.73 | $457.7K |
| 2026-04-15 | GOLDSMITH MARK A | See Remarks | Sell (open market) | 120.0K | $150.09 | $18.01M |
| 2026-03-25 | Anthony Mancini | See Remarks | Option exercise | 37.5K | $33.62 | $1.26M |
| 2026-03-25 | Anthony Mancini | See Remarks | Sell (open market) | 1.8K | $93.22 | $167.8K |
| 2026-03-25 | Anthony Mancini | See Remarks | Sell (open market) | 3.1K | $94.16 | $294.5K |
| 2026-03-25 | Anthony Mancini | See Remarks | Sell (open market) | 21.1K | $95.49 | $2.01M |
| 2026-03-25 | Anthony Mancini | See Remarks | Sell (open market) | 11.0K | $96.43 | $1.06M |
| 2026-03-25 | Anthony Mancini | See Remarks | Sell (open market) | 400 | $97.21 | $38.9K |
| 2026-03-19 | Jeff Cislini | General Counsel | Sell (open market) | 1.2K | $97.44 | $113.3K |
1–10 of 41
第 1 页 / 共 5 页